Loading...
Of men who undergo radical prostatectomy for clinically organ-confined prostate cancer, 30% to 40% will experience prostate-specific antigen (PSA) biochemical failure. Retrospective studies have demonstrated the potential for salvage radiotherapy to delay the development of metastatic disease.
Investigators have now analyzed data from a randomized, double-blind, placebo-controlled trial to determine whether augmenting primary radiotherapy with androgen deprivation therapy (ADT) can improve overall survival (OS) in 760 men (median age, 65; PSA level, 0.6) with clinically localized prostate cancer who underwent radical prostatectomy with lymphadenectomy. Patients had T2 disease with positive surgical margins or T3 without nodal involvement and…